Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
25.31
-0.30 (-1.17%)
At close: Sep 12, 2025, 4:00 PM EDT
25.42
+0.11 (0.43%)
After-hours: Sep 12, 2025, 6:52 PM EDT
Twist Bioscience Revenue
Twist Bioscience had revenue of $96.06M in the quarter ending June 30, 2025, with 17.91% growth. This brings the company's revenue in the last twelve months to $362.27M, up 22.72% year-over-year. In the fiscal year ending September 30, 2024, Twist Bioscience had annual revenue of $312.97M with 27.69% growth.
Revenue (ttm)
$362.27M
Revenue Growth
+22.72%
P/S Ratio
4.15
Revenue / Employee
$392,495
Employees
923
Market Cap
1.53B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TWST News
- 10 days ago - Twist Bioscience to Present at Baird 2025 Global Healthcare Conference - Business Wire
- 11 days ago - Twist Bioscience Collaborates with Synthetic Design Lab - Business Wire
- 16 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 25 days ago - Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution - Business Wire
- 4 weeks ago - Twist Bioscience: Headwinds Are Mounting - Seeking Alpha
- 5 weeks ago - Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors - Business Wire
- 5 weeks ago - Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings - Benzinga
- 5 weeks ago - Twist Bioscience Corporation (TWST) Q3 2025 Earnings Call Transcript - Seeking Alpha